Tag: biosimilars
Learn how the 12-year biologic exclusivity rule under the BPCIA delays biosimilar entry, impacting drug prices and patient access in the US compared to global markets.
Generic drugs saved the U.S. healthcare system $3.4 trillion from 2015-2024. Learn how Hatch-Waxman, biosimilars, and market competition drive these massive savings and what challenges remain.
A deep dive into the Asian generic pharmaceutical landscape, comparing India's volume dominance with China's API control and the rise of emerging hubs.
Biosimilars aren't exact copies of biologics - tiny manufacturing differences can trigger immune responses. Learn why some patients develop antibodies, how administration and genetics affect risk, and what real-world data really shows.
Medications
Archives
Recent-posts
Long-term safety studies: comparing generics and brands over time
Feb, 16 2026
Environmental Risk Factors for Rhabdomyosarcoma: What You Need to Know
Sep, 28 2025
How the FDA Monitors Generic Drug Safety After Approval
Dec, 7 2025
Deficiency Letters in Generic Drug Applications: Common FDA Findings and How to Avoid Them
Jan, 16 2026
How to Coordinate Care between OB/GYN and Psychiatrist for Medications During Pregnancy
May, 28 2026